Projekt · Dnr 2024-00074 · Källa: Vinnova
E!4692, VASIP, Intervacc
- Koordinator
- Intervacc AB
- Projekttid
- 2024-04-01 till 2027-03-31 (beslutat)
- Beviljat bidrag
- 5 000 000 SEK
- Diarienummer
- 2024-00074
Beskrivning
Streptococcus suis (S. suis) is an important endemic pathogen generating significant economic losses in the pig industry worldwide. Piglets develop disease post-weaning at between 4 and 10 weeks of age as the levels of maternal antibodies, which were passively acquired via the consumption of colostrum, wane. In this project we will develop and optimise the manufacturing process for a new fusion protein vaccine and measure the protection provided against a diverse type of S. suis, directing the design of clinical trials. This project will generate scaleable processes for the vaccine components, which are suitable for the manufacture of vaccine doses for use in clinical trials and commercial production. The project will also measure the protection that is provided by the vaccine against a diverse type of S. suis, and determine if specific antibody responses that are generated by vaccination correlate with the observed protection in piglets.
Hittar Vinnova inte sidan? Sök på diarienumret hos Vinnova.
Liknande
-
E!12402, VASIP, Vaccine Against Streptococcus suis Infections in Pigs, Intervacc AB
Intervacc AB · 2018-11-01 · 5 000 000 SEK · Projekt
Streptococcus suis is an important endemic pathogen of piglets, causing meningitis, arthritis, endocarditis and septicaemia with mortality rates of between 1% and 20%. Piglets are most susceptible to infection in the period immediately post-weaning leading to treatment with antibiotics and significa…
-
Nytt vaccin mot mastit hos nötkreatur orsakad av Staphylococcus aureus
Intervacc AB · 2020-05-01 · 1 943 296 SEK · Projekt
Mastitis is one of the most important diseases in dairy cattle causing significant losses to the dairy industry. Staphylococcus aureus is the causative agent of around 25% of contagious mastitis cases in Europe, accounting for over 2.6 million cases at an annual cost of 597M€. This project aimed to …
-
Nytt effektivt Stafylokockus aureus vaccin mot Mastit som ersätter antibiotikaanvändning
SAVACC AB · 2019-05-30 · 890 000 SEK · Projekt
SLU är ett universitet och fordrar publisering. Ett Staphylococcus aureus (SA) vaccin har framställt som är innovativt både vad gäller antigen och adjuvans. Det har framkallat potenta antikrops nivåer me blod serum och mjölk. Vi tror SAvaccinet skall framakalla skudseffekt The test vaccine Chrivacc …
-
E!11019, OptiFemVac, Abera Bioscience AB
Abera Bioscience AB · 2017-04-01 · 2 351 980 SEK · Projekt
The purpose was to engineer bacterial outer membrane vesicles (OMVs) into a versatile and modular platform for recombinant vaccine development. Technology was developped to couple high amounts of antigenic proteins to OMV particles and vaccine candidates against either Zika virus or Humano papiloma …
-
Preparedness and supply of pandemic influenza vaccine
Folkhälsomyndigheten · 2025-08-26 · 1 000 000 000 SEK · Upphandling
The Public Health Agency of Sweden invites tenderers to request to participate to tender for the provision of services for preparedness and supply of pandemic influenza vaccine. The goal is to award an Advanced Purchase Agreement (APA) to two or more suppliers, to be responsible for the supply and d…